Precision medicine startup Aqtual raised $31 million in an oversubscribed Series B round to develop its cell-free DNA-based assay designed to predict patient response to rheumatoid arthritis therapies. The funding includes strategic investors and will support enrollment in its PRIMA-102 clinical trial, which has over 1,300 participants. The company plans to present new data and commercialization strategies at upcoming rheumatology and diagnostics conferences. Aqtual’s platform aims to capture chronic disease biology for more effective personalized treatment planning.